Controlling Moral Hazard in Health Insurance: 4 Policy Tools & Tradeoffs

Added:

The Nyman Model and Value-Based Insurance Design (VBID)

Critics of the traditional 'moral hazard' framework, such as health economist John Nyman, argue that standard cost-control policies are based on a flawed premise. While conventional theory views insurance-induced demand as inefficient waste, the 'Nyman Model' demonstrates that much of this utilization represents an 'income transfer' effect. Insurance transfers resources to sick individuals, enabling them to access high-value, life-saving treatments they otherwise could not afford, which actually increases societal welfare. Additionally, proponents of Value-Based Insurance Design (VBID) point out that blunt policy tools like uniform cost-sharing are clinically blind. Evidence shows that when faced with higher costs, patients reduce their use of essential, high-value services (such as insulin) just as much as low-value services. This underuse of necessary care leads to worse health outcomes and higher downstream hospitalization costs. Therefore, critics advocate for clinically nuanced pricing that lowers barriers for high-value services, rather than using punitive, blanket restrictions to curb utilization.

The fundamental definition of 'moral hazard' in economics and how insurance coverage alters consumer behavior.
The concept of asymmetric information in market transactions and how it leads to market failures.
Basic health insurance structures, including the roles of premiums, deductibles, and co-payments.
The price elasticity of demand for healthcare services, indicating how consumer demand changes with out-of-pocket costs.
Empirical literature on moral hazard, specifically key findings from major health policy trials like the RAND Health Insurance Experiment.
Value-Based Insurance Design (VBID) and how behavioral economics can align consumer cost-sharing with clinical value.
Provider-payment reform models, including Accountable Care Organizations (ACOs), bundled payments, and global capitation systems.
Comparative healthcare systems analysis, examining how different nations (e.g., the UK's NHS vs. the US system) utilize gatekeeping and wait times to manage scarce resources.
939 views5likes9:08@hpam621healtheconomicscuny8Original Release: 2020-04-07

Moral hazard in healthcare insurance can be controlled through four main policy tools: (1) Cost-effectiveness analysis, which evaluates treatment options to maximize health outcomes per dollar spent but may be politically controversial; (2) Cost-sharing mechanisms like deductibles and co-payments that make patients more cost-conscious but can reduce affordability and equity; (3) Gatekeeping and queuing systems that require patients to see primary care physicians first, which can limit specialist access and create wait times but may be more equitable than cost-sharing; and (4) Prospective payment systems that pay fixed amounts based on diagnosis rather than services rendered, which incentivizes cost control but may create adversarial doctor-patient relationships and potentially compromise care quality. Each approach involves trade-offs between efficiency, equity, and political feasibility.